Navigation Links
Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan and Transfer to Nasdaq Capital Market
Date:12/16/2010

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2010 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that it has provided notice of voluntary prepayment of its senior secured loan facility to GE Business Financial Services Inc. and Silicon Valley Bank.  The Company expects to pay the approximately $12.3 million balance on the facility, including interest and other fees payable under the loan agreement, prior to year-end.  Once repaid, all covenants and restrictions related to the facility will lift, including lender consent requirements restricting certain asset sales, mergers and acquisition transactions and financial covenants requiring the Company to maintain a minimum amount of unrestricted cash.

The Company also announced today that it received approval from the Nasdaq Stock Market Listing Qualifications Staff to transfer the listing of its common stock from The Nasdaq Global Market to The Nasdaq Capital Market.  This transfer will be effective at the opening of business on Friday, December 17, 2010, and the Company's common stock will continue to trade under the symbol "PARD."  The Nasdaq Capital Market is a continuous trading market that operates in substantially the same manner as The Nasdaq Global Market.  All companies listed on The Nasdaq Capital Market must meet certain financial requirements and comply with Nasdaq's corporate governance requirements.

"The steps taken today serve to free up capital and assets as well as maintain the continued liquidity of our common stock and Nasdaq listing status as we continue our ongoing review of strategic alternatives aimed at optimizing the value of the Company and of our lead program, picoplatin," said Ronald A. Martell, chief executive officer of Poniard Pharmaceuticals.  "We continue t
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals Reports Third Quarter 2010 Financial Results
2. Poniard Pharmaceuticals Awarded $244,479 Grant Under Qualifying Therapeutic Discovery Project Program
3. Poniard Pharmaceuticals Receives NASDAQ Deficiency Notice Related to Minimum Bid Price
4. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
5. Poniard Pharmaceuticals Announces $6.3 Million Financing
6. Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
7. Poniard Pharmaceuticals to Present at 12th Annual BIO CEO and Investor Conference
8. Poniard Pharmaceuticals Announces Management Changes and Reduction in Force
9. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
10. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
11. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 Nanomix Inc., (Nanomix), a ... of mobile diagnostic tests to enable earlier ... pre-hospital settings, today announced it has received ... certification was awarded by the British Standards ... certification bodies. ISO 13485:2003 ...
(Date:11/26/2014)... LONDON , Nov. 25, 2014 Amgen ... AZN ) today announced that AMAGINE-2 TM , a pivotal, ... more than 1,800 patients with moderate-to-severe plaque psoriasis, met its ... and placebo at week 12. Brodalumab 210 mg given every ... shown to be superior to Stelara on the primary endpoint ...
(Date:11/26/2014)... SHENZHEN, China, Nov. 26, 2014 China Nepstar ... the "Company"), a leading retail drugstore chain in China ... announced its unaudited financial results for the third quarter ... ended September 30, 2014: , Same store sales increased ... , Revenue increased by 8.1% to RMB738.3 million (US$120.3 ...
Breaking Medicine Technology:Nanomix Receives ISO 13485:2003 Certification 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 11
... 2010 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... of medical devices worldwide, today announced its participation in ... Trade Fair with Congress, to be held November 17-20, ... well over 100 countries are expected to attend this ...
... Nov. 11, 2010 Dynatronics Corporation (Nasdaq: DYNT ) ... 2010. Sales for the quarter ended September 30, 2010 ... 2009. Net income for the quarter ended September 30, 2010, was ... share) for the same quarter in the prior fiscal year. ...
Cached Medicine Technology:Mindray Medical to Exhibit at MEDICA 2010 in Dusseldorf, Germany from November 17- 20, 2010 2Mindray Medical to Exhibit at MEDICA 2010 in Dusseldorf, Germany from November 17- 20, 2010 3Dynatronics Announces Fiscal First Quarter Results 2Dynatronics Announces Fiscal First Quarter Results 3
(Date:11/26/2014)... Senior Planning Services, providing “expert guidance for elder ... the adult demographic education and access to computer ... rough seas of applying for Medicaid. Part of this ... of Medicaid eligibility and proper planning, while also helping ... this coverage. , Senior Planning Services has made ...
(Date:11/26/2014)... IL (PRWEB) November 26, 2014 ... communication management solutions, has been award the ... Magazine. , This award comes as a great ... capabilities within the Lync ecosystem. Specifically, ISI offers ... all modes of Lync communication, including voice, video, ...
(Date:11/26/2014)... Albany, NY (PRWEB) November 26, 2014 ... industry research requirements or email the details on sales(at)researchmoz(dot)us ... "Worldwide diabetes and drug discovery market 2014" with deep ... Diabetes is the result of high blood sugar. The ... is directly linked to the growing number of diabetics ...
(Date:11/26/2014)... 2014 Bunion Bootie, the newest and ... an early celebration of the early holiday shopping season. ... at the promotional price of $29.95 each (normally $33.95 ... to any automatic discounts applied when buying more than ... for complete details. It’s simple: purchasing more Bunion ...
(Date:11/26/2014)... 2014 Louisiana Back Institute, leaders ... in minimally invasive spine surgery, announces today the ... rapidly growing provider network of orthopedic spine surgeons ... with the network’s continuing success providing the most ... residents who are suffering from orthopedic spine conditions ...
Breaking Medicine News(10 mins):Health News:Senior Planning Services Teams Up with SeniorNet To Educate Seniors On Medicaid Planning 2Health News:ISI Telemanagement Solutions, Inc. has been Awarded the 2014 Microsoft Lync Pioneer Award 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Bunion Bootie Temporarily Lowering Prices for Holiday Shopping, Starting Today! 2Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2
... The most poisonous substance on Earth already used medically ... wrinkles could be re-engineered for an expanded role in ... other diseases, scientists are reporting. Their study appears in ACS, ... that toxins, or poisons, produced by Clostridium botulinum ...
... HealthDay Reporter , TUESDAY, Nov. 29 (HealthDay ... hip replacement devices appear to work the same, a ... seem to be no more effective than older implants ... said. "Metal-on-metal and ceramic-on-ceramic hip implants might not ...
... Findings on coronary CT angiography (CTA), a noninvasive test to ... for men and women, according to a study presented today ... artery disease (CAD) is a narrowing of the blood vessels ... caused by a build-up of fat and other substances that ...
... TUESDAY, Nov. 29 (HealthDay News) -- Men are less willing ... have higher cancer death rates, a new study shows. ... New York City, Baltimore, and San Juan, Puerto Rico, who ... participants were aged 30 to 59, and 35 percent of ...
... Gass, MD, chief of surgery at Women & Infants Hospital ... Health Center in the hospital,s Program in Women,s Oncology, recently ... surgeon Krishna B. Clough, MD, medical director of the Paris ... novel surgical technique available to breast cancer patients through Women ...
... HOUSTON -- Combination treatment with everolimus, an inhibitor ... has shown to improve progression-free survival for patients ... carcinoid syndrome, according to researchers at The University ... of the international, randomized, placebo-controlled Phase III study ...
Cached Medicine News:Health News:New Hip Implants No Better Than Older Ones, Study Finds 2Health News:New Hip Implants No Better Than Older Ones, Study Finds 3Health News:Heart attack risk differs between men and women 2Health News:Men More Likely to Skip Cancer Screenings: Study 2Health News:Surgeon studies with world-renowned oncoplastic pioneer 2Health News:Surgeon studies with world-renowned oncoplastic pioneer 3Health News:Everolimus prolongs progression-free survival for patients with neuroendocrine tumors 2Health News:Everolimus prolongs progression-free survival for patients with neuroendocrine tumors 3
... Pulsavac Wound Debridement System ... for pulsatile irrigation,and debridement. ... range of fluid pressure ... lavage to a penetrating ...
... Amsco 3085 SP Surgical Table provides state-of-the-art ... now be networked with the HERMES Control ... Stryker Endoscopy) to allow the surgeon direct ... surgeon uses either simple voice commands or ...
... The ASC 2000 is ... care table, meeting good manufacturing ... regulatory requirements. It provides electro-hydraulic ... accessories for all ambulatory surgical ...
... The hands play an important part ... traumatic impairments and rheumatic changes can cause ... developing of the finger-joint prostheses was to ... reproduce the natural function as nearly possible.,The ...
Medicine Products: